PEComa
Revision as of 20:33, 11 August 2023 by Warner-admin (talk | contribs) (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|")
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
nab-Sirolimus monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence | |
|---|---|---|---|
Wagner et al. 2021 (AMPECT)
|
2016-2018 | Phase 2 (RT) |
Targeted therapy
- Sirolimus protein-bound particles (Fyarro) 100 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- AMPECT: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02494570